New drug cocktail targets tough leukemia
NCT ID NCT07614022
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called LP-118 alongside standard treatments for adults newly diagnosed with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 26 people to find the safest dose and see if the combination helps control the disease. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LP-118 (a Bcl-2/Bcl-XL inhibitor) given with ponatinib, dexamethasone, and blinatumomab
- What this could lead to
- If it works, this could point toward a more effective treatment for a rare, aggressive leukemia, potentially improving remission rates.
- What could go wrong
- This is a very early Phase 1 trial with only 26 people, so safety and dosing are the main focus. The drug combination may cause serious side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Levine Cancer
Charlotte, North Carolina, 28204, United States
-
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.